Journal
CELLS
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cells11020223
Keywords
myelodysplastic syndrome; Azacytidine; resistance; CDX mice; PI3K; AKT signaling
Categories
Ask authors/readers for more resources
Through the development of cellular models, researchers identified cancer-related pathways that play a crucial role in the resistance of myelodysplastic syndrome (MDS) cells to hypomethylating agents (HMA) and their progression to acute myeloid leukemia (AML). These pathways can be modulated by specific inhibitors, but do not increase the sensitivity of the cells to HMA.
The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive research. A better understanding of mechanisms by which the MDS cell becomes to tolerate HMA and progresses to acute myeloid leukemia (AML) requires the development of new cellular models. From MDS/AML cell lines we developed a model of 5-azacytidine (AZA) resistance whose stability was validated by a transplantation approach into immunocompromised mice. When investigating mRNA expression and DNA variants of the AZA resistant phenotype we observed deregulation of several cancer-related pathways including the phosphatidylinosito-3 kinase signaling. We have further shown that these pathways can be modulated by specific inhibitors that, while blocking the proliferation of AZA resistant cells, are unable to increase their sensitivity to AZA. Our data reveal a set of molecular mechanisms that can be targeted to expand therapeutic options during progression on AZA therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available